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ABSTRACT
Colorectal cancer (CRC) is the third diagnosed cancer and the second leading 
cause of cancer-related deaths in the United States. Colorectal cancer is linked to 
inflammation and phospholipase Cγ1 (PLCγ1) is associated with tumorigenesis and 
the development of colorectal cancer; however, evidence of mechanisms connecting 
them remains unclear. The tight junctions (TJ), as intercellular junctional complexes, 
have an important role for integrity of the epithelial barrier to regulate the cellular 
permeability. Here we found that PLCγ1 regulated colitis and tumorigenesis in 
intestinal epithelial cells (IEC). To induce the colitis-associated cancer (CAC), we 
used the AOM/DSS model. Mice were sacrificed at 100 days (DSS three cycles) and 
120 days (DSS one cycle). In a CAC model, we showed that the deletion of PLCγ1 in IEC 
decreased the incidence of tumors by enhancing apoptosis and inhibiting proliferation 
during tumor development. Accordingly, the deletion of PLCγ1 in IEC reduced colitis-
induced epithelial inflammation via inhibition of pro-inflammatory cytokines and 
mediators. The PLCγ1 pathway in IEC accelerated colitis-induced epithelial damage 
via regulation of TJ proteins. Conclusions: Our findings suggest that PLCγ1 is a critical 
regulator of colitis and colorectal cancer and could further help in the development 
of therapy for colitis-associated cancer.
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INTRODUCTION
Cancer comprises a large family of diseases that 
is characterized by abnormal cell growth and invasion 
of surrounding tissues. Cancer cells undergo modified 
cellular processes, such as cell proliferation, migration, 
and differentiation, using altered signaling pathways. 
Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer and the second leading cause of 
cancer-related deaths in the United States. Various 
mutations have been associated with the development 
of CRC, including the Wnt signaling pathway, K-Ras, 
p53, and the transforming growth factor β pathway [1, 2]. 
Cancer-associated inflammation, as a hallmark of cancer, 
is an important factor in the development of CRC; other 
environmental factors, such as epigenetic abnormalities 
and genetic mutations also play important roles in 
this process [3–5]. It has been reported that chronic 
inflammation is the leading cause of increased risk of 
several types of cancers including colon, liver, prostate, 
and breast cancer [6, 7]. Patients with inflammatory 
bowel disease (IBD), such as Crohn’s disease and 
ulcerative colitis, have a higher risk of developing 
CRC compared with healthy people. IBD, which is 
characterized by chronic inflammatory conditions 
of the gastrointestinal (GI) tract, results not only in 
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intestinal epithelial barrier disruption but also in an 
influx of immune cells [8–10]. Tight junctions (TJs) 
of the intestinal epithelium play a pivotal role in the 
regulation of barrier function and protect the body from 
toxins, allergens, and pathogens in the intestine. IBD has 
been associated with an increased risk of CRC and the 
development of CRC between the stages of inflammation 
and carcinogenesis. This link between inflammation and 
the development of CRC has been extensively studied 
using mouse models of defects in the epithelial barrier in 
colitis and the formation of colorectal tumor. However, 
the contributing factors and underlying mechanisms have 
yet to be identified. 
Phosphoinositide-specific phospholipase C (PLC) 
regulates cellular ligand-mediated signal transduction. 
PLC hydrolyzes phosphatidylinositol-4,5-bisphosphate 
(PIP2) into inositol-1,4, 5-triphosphate (IP3) and 
diacylglycerol (DAG). PLCs are activated by various 
extracellular ligands, such as growth factors, hormones, 
cytokines, and lipids. Several studies have shown that 
the activation of PLCs is associated with tumorigenesis 
and/or the progression of metastasis, such as migration, 
proliferation, growth, inflammation, angiogenesis, and 
the rearrangement of the actin cytoskeleton. As one of 
13 mammalian PLC isozymes, PLC gamma 1 (PLCγ1) 
is primarily activated by extracellular stimuli and is 
involved in tyrosine kinase signaling and the promotion 
of tumor cell growth and migration [11, 12]. There is 
also evidence that PLCγ1 plays a critical role in cell 
adhesion and is highly expressed in metastatic tumors 
[13]. A genetic deficiency in PLCγ1 was shown to play 
an important role in metastasis and anti-apoptosis of 
human CRC, indicating that PLCγ1 can function as a 
oncogene in vitro [14]. 
Despite the increasing number of studies 
seeking to identify the possible link between PLCγ1 
and tumorigenesis, the pathogenic role of PLCγ1 in 
inflammation-related cancers, particularly colitis-
associated cancer (CAC), has yet to be investigated. The 
present study is the first to use intestine-specific PLCγ1 
conditional knockout mice as an experimental model to 
investigate the role of PLCγ1 in intestinal inflammation 
and CAC. Ablation of PLCγ1 in intestinal epithelial cells 
(IECs) significantly ameliorated CAC progression. Our 
study sought to identify the role of PLCγ1 in tumorigenesis 
under physiological conditions.
RESULTS
Deletion of PLCγ1 in IECs decreases the 
incidence of CAC
Azoxymethane (AOM) acts as a carcinogen via 
the formation of O
6
-methyl guanine [15]. AOM/dextran 
sulfate sodium salt (DSS) was shown to induce tumors 
in the colons of rodent (distal to middle segments) and 
is commonly used in experimental CRC animal models 
[16]. We generated PLCγ1 IEC-specific knockout mice 
using Villin-Cre and PLCγ1 alleles to investigate the 
effects of the PLCγ1 deletion on IECs. We designed 
two experimental protocols to test the effects of 
inflammation on CAC. In the first study, 6–8 week-
old mice were intraperitoneally (IP) injected with a 
single 10 mg/kg-dose of AOM followed by one or three 
cycles of 2% DSS administered in the drinking water 
(Figure 1A and 1E). Repeated DSS administration, used 
to mimic IBD, was conducted to cause AOM-induced 
tumors [17]. PLCγ1 conditional knockout mice and 
PLCγ1f/f [wild type (WT)] littermates developed colon 
tumors, primarily in the distal to middle segments, using 
the AOM/DSS protocol (Figure 1B, 1D, 1F, 1G and 1H), 
consistent with the localization of human colorectal 
tumors, the most severe consequence of DSS-induced 
colitis [18]. However, mice receiving DSS alone did not 
produce tumors during the experimental period (data not 
shown). When PLCγ1 conditional knockout mice were 
subjected to three cycles of DSS, we observed a 50% 
decrease in the incidence of tumors, and the average 
tumor load was lower than that in WT mice. In addition, 
macroscopic tumors (>4 mm) were detected only in WT 
mice (Figure 1C). Histological analyses showed more 
low- and high grade tumors in WT mice than in PLCγ1 
conditional knockout mice, but the relative proportion 
of low- versus high grade tumors was similar in both 
mouse groups. When mice were subjected to only one 
cycle of DSS (Figure 1E), we noticed that WT mice 
only manifested colon tumors, whereas no colon 
tumors were detected in PLCγ1 conditional knockout 
mice (Figure 1F and 1H). In addition, the incidence 
of tumors in WT mice undergoing one cycle of DSS 
was reduced by approximately 50% compared with WT 
mice undergoing three cycles of DSS. 
This result suggests that the difference between the 
incidence of tumors causing an inflammatory response 
and the frequency of DSS administration is due to the 
effects of PLCγ1 on inflammatory responses caused 
by DSS and on both tumor initiation and development. 
Adenomatous polyposis coli (APC) or β-catenin gene 
mutations lead to increased tumor incidence through the 
stabilization of β-catenin and transcriptional activation 
with TCF-4, which play a pivotal role in CRC [19]. 
Genomic DNA from the tissue was isolated using laser 
capture microdissection and purified; exon 3 of the 
β-catenin gene was sequenced to look for mutations. 
We found that exon 3 of the β-catenin gene, which 
corresponds to a GSK3β phosphorylation sites, contained 
a serine-to-cysteine mutation in codon 33 in both WT 
and PLCγ1 conditional knockout mice (Supplementary 
Figure 1). These results suggested that the severity 
of inflammation is associated with increased tumor 
incidences and that PLCγ1 plays a pivotal role in tumor 
initiation and/or promotion.
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Deletion of PLCγ1 in IECs reduces proliferation 
and induces apoptosis in CAC
Apoptosis is involved in tumor progression and 
maintenance. PLCγ1 regulates apoptosis enzymatically 
by proteolytic cleavage [20, 21]. We found that AOM/
DSS induces apoptosis more strongly in PLCγ1 
conditional knockout mice than in WT mice. As 
expected, PLCγ1 was strongly expressed in the AOM/
DSS tumor model, whereas it was expressed at 
approximately normal levels in WT mice (Figure 2A). 
Numbers of cleaved caspase-3 positive cells were 
decreased in WT mice compared to those in PLCγ1 
conditional knockout mice (Figure 2B). Analyses of 
apoptosis-related proteins revealed that the levels of 
the proapoptotic protein Bak and cleaved poly (ADP-
ribose) polymerase (PARP) were significantly increased, 
whereas levels of phospho-AKT, phosphor-STAT3, 
and phospho-p65 were decreased in PLCγ1 conditional 
knockout mice. In contrast, Bax and Bcl-XL were 
expressed at similar levels in WT and PLCγ1 conditional 
knockout mice. The activation of c-Jun N-terminal 
Figure 1: Deletion of PLCγ1 in IECs decreases AOM/DSS-induced tumor incidence in colorectal ducts. (A) Design of the 
AOM/DSS protocol (DSS three cycles). (B) Representative images of colon tumors. (C) Average tumor number, load, and size distribution. 
Data represent the means ± SEM (n ≥ 6). *p < 0.05. (D) H&E staining of tumors (E) Schematic representation of the AOM/DSS protocol 
(DSS one cycle). (F) Representative images of colon tumors. (G) Average tumor number, load, and size distribution. Data represent the 
means ± SEM (n ≥ 6). (H) H&E staining of tumor morphology.
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kinase has been shown to induce apoptosis [22, 23]. 
However, the expression levels of mitogen-activated 
protein kinases were not changed (Figure 2C). We used 
terminal deoxynucleotidyl transferase-mediated dUTP 
nick- end- labeling (TUNEL) to investigate apoptotic 
responses in tumors from WT and PLCγ1 conditional 
knockout mice (Figure 2D). In contrast to WT mice, 
TUNEL-positive cells were detected in tumors isolated 
from PLCγ1 conditional knockout mice. The decrease in 
tumor incidence could explain the increase in apoptosis 
by the upregulation of Bak and cleaved PARP, and 
the downregulation of phospho-AKT, in tumors from 
PLCγ1 conditional knockout mice. The proliferation of 
tumor cells plays a critical role in tumor development; 
previous studies showed that PLCγ1 is essential for cell 
proliferation and differentiation [24, 25]. We tested cell 
proliferation in colon tumors from AOM/DSS-treated 
mice. We detected dividing tumor cells using p-histone 
H3 immunohistochemistry (IHC) and found higher 
proliferation rates in tumors from WT mice compared 
to PLCγ1 conditional knockout mice. Consistent with 
hematoxylin and eosin (H&E) staining, the proliferation 
of tumor cells was much higher in WT mice than 
in PLCγ1 conditional knockout mice during tumor 
progression and development (Figure 2D). These results 
suggest that the difference in tumor incidence caused by 
apoptosis and proliferation of tumor cells occurs through 
the activation of PLCγ1.
Figure 2: In the AOM/DSS model, deletion of PLCγ1 in IECs decreases tumor incidence by increasing apoptosis and 
inhibiting proliferation. (A) Western blotting of PLCγ1 in whole-colon lysates (colon). (B) Colon tumor tissues were obtained from 
PLCγ1f/f (WT) and PLCγ1 conditional knockout mice, and samples were stained for cleaved caspase-3. (C) Colon tumor tissues were 
obtained from PLCγ1f/f and PLCγ1 conditional knockout mice, and samples were analyzed by western blotting (one mouse per lane) 
with the indicated antibodies. Data represent the means ± SEM (n = 3). (D) Colon tumor tissues were obtained from PLCγ1f/f and PLCγ1 
conditional knockout mice, and samples were stained for H&E staining, and p-Histone H3, and used for TUNEL assay.
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IEC-specific deletion of PLCγ1 prevents DSS-
induced inflammation
Although a recent study did not report any 
direct evidence for the effects of PLCγ1 inhibition 
on attenuated colonic inflammation, we hypothesize 
that PLCγ1 contributes to the inflammatory response, 
including via the NF-κB signaling pathway [26]. To 
assess whether PLCγ1 may affect colonic inflammation, 
we applied the DSS-induced acute colitis model in 
PLCγ1 conditional knockout mice and their littermate 
controls (Figure 3A). This method provides an 
indication of the mechanisms behind the initiation and/
or development of AOM/DSS-induced tumors [27]. 
After three days of DSS administration, WT mice lost 
more body weight than did PLCγ1 conditional knockout 
mice (Figure 3B), which is an induction of the severity 
of DSS-induced colitis. Another indicator, DSS-induced 
shrinkage in colon length did not differ between PLCγ1 
conditional knockout mice and WT mice (Figure 3C). 
The expression of PLCg1 also did not differ between 
DSS-treated WT mice and PLCγ1 conditional knockout 
mice (Figure 3D). These results suggest that PLCγ1 
stimulates inflammation and IEC damage. To confirm 
this hypothesis, mice were provided DSS and analyzed 
three, five, and eight days. At each time point, the 
colons of WT mice presented mild to severe colonic 
inflammation and a disrupted intestinal architecture, 
whereas the colons of PLCγ1 conditional knockout 
mice presented moderate to mild inflammation and 
a maintained intestinal architecture (Figure 4). In 
particular, WT mice had more infiltrating cells and 
fewer goblet cells compared to PLCγ1 conditional 
knockout mice after eight days (Figure 4). We also 
found that DSS-treated WT mice showed significantly 
more damage to IECs in the distal-to middle segments 
of the colon compared to PLCγ1 conditional knockout 
mice (data not shown).
Deletion of PLCγ1 in IECs reduces DSS-induced 
inflammation 
AOM and various alkylating agents induce rapid 
p53-dependent apoptosis of IECs by stimulating DNA 
damage [22]. We investigated whether AOM may further 
enhance apoptosis in PLCγ1 conditional knockout mice. 
However, AOM alone did not contribute to apoptosis 
via DNA damage in PLCγ1 conditional knockout mice 
(Supplementary Figure 2). These results suggest that the 
variability in tumor frequency between WT and PLCγ1 
conditional knockout mice was not caused by AOM-
induced DNA damage or apoptosis.
Figure 3: Deletion of PLCγ1 in IECs decreases DSS-induced colitis. (A) Schematic representation of the acute colitis protocol. 
(B) DSS was administered in drinking water for five days, and body weight was recorded. Data are the means ± SEM (n ≥ 10), *p < 0.05. 
(C) PLCγ1f/f (WT) mice exhibit colon shortening after eight days of treatment with 3% DSS compared with PLCγ1 conditional knockout 
mice. Data represent the means ± SEM (n ≥ 10). *p < 0.05. (D) Colon lysates were obtained from DSS-treated mice, and the expression of 
PLCγ1 by western blotting (one mouse per lane) was analyzed.
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During colonic inflammation, cytokines and 
chemokines from infiltrating immune cells play crucial 
roles in intestinal tissues. We found that mRNA levels 
of cytokines, including interleukin (IL-) 6, tumor 
necrosis factor alpha, IL-1β, and cyclooxygenase-2, 
were significantly increased in colons from DSS-treated 
PLCγ1 conditional knockout mice compared to WT mice 
(Figure 5A). IL-6 levels increased more in WT mice 
than the other cytokines, because the PLCγ1 pathway 
is linked to IL-6 signaling [28, 29]. The upregulation 
of IL-6 enhanced inflammation via the infiltration of 
immune cells by paracrine and/or autocrine mechanisms 
[30]. In addition, we detected higher expression levels of 
inflammation-mediated transcription factors such as IκB, 
nuclear factor (NF)-κB, and STAT3; resulting in a decrease 
in the phosphorylation of both STAT3 and NF-κB by the 
activation of IκB in PLCγ1 conditional knockout mice 
(Figure 5B). Taken together, these results demonstrate that 
decreased tumor incidence in PLCγ1 conditional knockout 
mice is due to reduced inflammation.
Deletion of PLCγ1 in IECs induces an intestinal 
barrier dysfunction after DSS treatment
Disrupted epithelial barrier function has been 
associated with IBD and colon cancer [8, 9]. Damage 
to IECs leads to inflammation of the colonic mucosa as 
a result of intestinal barrier dysfunction in patients with 
ulcerative colitis [31]. Levels of IL-6 are increased in IBD 
patients, which modulated the expression of TJ proteins 
both in vivo and in vitro [32, 33]. We identified upregulated 
IL-6 levels in WT mice compared with PLCg1 conditional 
knockout mice. We hypothesized that the DSS-induced 
enhancement of IEC damage and increasing inflammation 
in WT mice triggered intestinal barrier dysfunction. As TJs 
are comprised of cytoplasmic scaffolding proteins, such as 
ZO, occludin, claudin, and dynamic structures [34], which 
play pivotal roles in TJ structure and function, and recent 
study found that PLCg inhibition enhanced epithelial 
barrier dysfunction via the regulation of TJ proteins [35], 
we chose to investigate the role of PLCg1 in intestinal 
barrier dysfunction by analyzing the expression of TJ 
proteins using IHC in DSS treated colon tissues. We found 
that the expression levels of TJ proteins were decreased in 
apical lesions of the intestinal epithelium and redistributed 
into colonic tissues after 5 days of DSS treatment in WT 
mice (Figure 6A) compared to the finding that TJ proteins 
were maintained in PLCg1 conditional knockout mice 
(Figure 6B). A difference in TJ proteins was observed 
after eight days of DSS exposure (Figure 6C). We also 
detected the expression of zonula occludens-1 (ZO-1) 
and protein kinase C alpha (PKCα) by western blotting. 
PKC activation regulates paracellular permeability via 
the activation of myosin light- chain kinase and the 
redistribution of ZO-1 [36]. We identified PKCα activation 
and ZO-1 downregulation in the colons of DSS-induced 
WT mice, and the mRNA levels of ZO-1 and occludin 
were significantly decreased (Figure 6C). In addition, 
mRNA levels and protein expression of ZO-1 and occludin 
were significantly decreased in colon tumors from AOM/
DSS-treated WT mice Supplementary Figure 3A and 3C), 
but mRNA levels of IL-6 did not change (Supplementary 
Figure 3B). Collectively, these results indicate that a 
reduction in inflammation after DSS treatment in PLCγ1 
conditional knockout mice is due to reduced intestinal 
barrier dysfunction via the inhibition of the PKC pathway 
and protection of TJ proteins.
DISCUSSION
CRC is one of the most common malignant tumors 
[37]. Several factors have been causally associated with 
Figure 4: Histological changes in mice with DSS-induced colitis. Decreased susceptibility of PLCγ1 conditional knockout mice 
treated with DSS to colitis. Colons of PLCγ1f/f (WT) and PLCγ1 conditional knockout mice were analyzed by H&E staining three, five, 
and eight days after 3% DSS exposure, and goblet cells were analyzed by Alcian Blue staining eight days after 3% DSS exposure. (A, G) 
control H&E staining. (C, I) 3 days H&E staining. (D, J) 5 days H&E staining. (E, K) 8 days H&E staining. (B, H) control Alcian Blue 
staining. (F, L) 8 days Alcian Blue staining.
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Figure 5: Deletion of PLCγ1 in IECs reduces DSS-induced inflammation. (A) Relative mRNA expression levels of the 
indicated genes in mouse colons were analyzed by qRT-PCR. Data are the means ± SEM (n ≥ 10), *p < 0.05. (B) IECs were isolated from 
PLCγ1f/f (WT) and PLCγ1 conditional knockout mice after DSS exposure, and samples were analyzed by western blotting (one mouse per 
lane) with the indicated antibodies.
Figure 6: Deletion of PLCγ1 in IECs increases intestinal barrier dysfunction. (A and B) DSS-induced IECs were obtained 
from PLCγ1f/f (WT) and PLCγ1 conditional knockout mice at three, five, and eight days, and samples were stained by IHC with the 
indicated antibodies. (C) Colon lysates were analyzed by western blotting and qRT-PCR. Data are the means ± SEM (n ≥ 10), *p < 0.05.
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the development of CRC [38]. This work was designed to 
investigate whether the deletion of PLCγ1 in IECs could 
reduce colitis-associated tumor incidence (CATI) through 
the induction of apoptosis. 
In CAC, the initial evidence for the functional 
relevance of PLCγ1 signaling was provided in a preclinical 
trial that demonstrated that many of these targets are 
associated with cancer initiation and progression [17]. 
Our data indicate that tumor progression depends on the 
frequency of DSS exposure, suggesting that inflammation 
is associated with PLCγ1 activation.
PLC hydrolyzes PIP2 into IP3 and DAG via IP3-
induced calcium release, and IP3 modulated DAG 
activates PKC [39]. Several studies have implicated 
PLCγ1 as a regulator of cancer cell invasion and metastasis 
via multiple mechanisms. PLCγ1 is a major transducer of 
growth factor and cytokine signaling. Downregulation of 
PLCγ1 has been shown to inhibit human breast cancer 
cell-derived lung metastasis and progression in mice [40]. 
In this study, PLCγ1 conditional knockout mice 
and WT littermates developed colon tumors, primarily in 
the distal to middle segments. Only WT mice developed 
macroscopic tumors (>4 mm) with a higher average 
tumor load and tumor number than in PLCγ1 conditional 
knockout mice (Figure 1). Previous reports demonstrated 
that mutation at an important serine residue in codon 
33 of β-catenin has a high oncogenic potential in AOM/
DSS-induced colon adenocarcinomas [41, 42]. Therefore, 
we confirmed the presence of this mutation in our mice 
and investigated its role in the mechanism of AOM/DSS-
induced colon cancer. Our results were consistent with 
those of previous reports [41, 42]. The mutation patterns 
in exon 3 of β-catenin were similar in both WT and PLCγ1 
knockout mice. These results demonstrate that AOM/DSS-
induces cancer using the same mechanism in both mouse 
groups.
AOM/DSS-treated mice consistently develop 
metastases; however, the absence of a control genetic 
mutation that can be activated by a carcinogen makes this 
model system of questionable utility [16]. PI(3)Kγ–/– and 
Apc1638N/+ mutants have been reported to develop colonic 
adenocarcinomas that metastasize to the lymph nodes and 
liver, which are common metastatic sites of human CRCs 
[16]. Activated STAT3 has been shown to be increased 
in CRC patients [43]; its activation induces certain anti-
apoptotic agents, such as Bcl-2 and Bcl-xl, which in turn 
increase CRC cell survival, proliferation, incursion, and 
lymph node metastasis [44]. Other studies have shown a 
correlation between STAT3 and Bak, which is probably 
related to the accumulation of proapoptotic molecules 
as well as to mediators of cell survival and growth [45]. 
PLCγ1 cleavage can be blocked by the overexpression of 
Bcl-2 and specific caspase inhibitors [20]. 
We examined whether PLCγ1 plays a pivotal role in 
IECs and whether AOM/DSS induces apoptosis in PLCγ1 
conditional knockout mice. In the AOM/DSS model, the 
PLCγ1, Bak, and cleaved PARP levels were significantly 
increased in tumors isolated from WT mice, whereas 
cleaved caspase-3 levels were decreased; however, 
in PLCγ1 conditional knockout mice, phospho-AKT, 
phospho-STAT3, and phospho-p65 were all decreased 
(Figure 2). Although results from a previous report 
indicated that the interaction between AKT and PLCγ 
was involved in cell growth and migration, the extent of 
cross-talk between their regulatory mechanisms remain 
unclear [46]. However, it is well known that AKT must 
be phosphorylated to stimulate cell proliferation through 
the activated PLCγ/ PKCγ/Src/PI3K pathway in epidermal 
growth factor stimulated conjunctival goblet cells [40]. 
Recently, major proinflammatory pathways have 
been implicated in inflammation-associated tumor 
development. The carcinogenic potential of AOM is 
markedly increased by chronic inflammation, such 
as that induced by repeated cycles of DSS treatment. 
Furthermore, it has been reported that the IL-6/STAT3 
signaling pathway plays an important role in AOM/DSS-
induced murine CAC [47]. To investigate the effects of 
PLCγ1 on CAC tumorigenesis, particularly on the IL-6/
STAT3 signaling pathway in AOM/DSS-treated mice, 
a deletion mutant of PLCγ1 was used in a tumorigenic 
model of CAC and was shown to prevent inflammation by 
inhibiting the phosphoryla tion of STAT3 on Tyr705 [48]. 
Here, we showed that the expression levels of STAT3 
phosphorylation were higher in WT mice than PLCγ1 
conditional knockout mice, leading to much higher tumor 
proliferation and inflammatory responses in the WT 
mice. As shown previously, the NF-κB-dependent tumor 
growth factor released by IECs could be IL-6, which plays 
an important role in proliferation [49] and can activates 
STAT3. Previous reports showed that DSS administration 
is well established to induce colitis, but removal of DSS 
leads to complete recovery of colitis to normalcy in 4–5 
days [50]. IL-6 plays important roles in tumor initiation 
via PLCγ1–mediated inflammatory response in colitis 
environment, and also after recovered colitis by removal 
of DSS, crosstalk between stat-3 and PLCγ1 is involved 
in tumor progression and development through apoptosis 
and proliferation. This result could elucidate the role of 
PLCγ1 in the suppression of the IL-6/STAT3 pathway; 
and provide further insight into the critical mechanisms 
involved (Figures 2C and 5).
The cellular localization of most PLCs is primarily 
cytosolic in the resting state; following receptor activation, 
PLCs are transiently recruited to the cell membrane. 
PLC-dependent pathways are postulated to be involved 
in the regulation of TJs [51]. In general, TJ formation 
is essential for early embryonic development, and PLCs 
may plays crucial roles in such developmental processes 
[52], a hypothesis supported by the developmental defects 
observed in various knockout mice lacking different PLC 
isozymes. PLCγ is known to contain SH3 domains that 
bind proline-rich motifs on target proteins; interestingly, 
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ZO proteins contain proline-rich sequences that could 
bind and localize PLCγ to TJs [53]. Although no reports 
have described the colocalization of PLCγ and TJs, PLC 
isozymes have been reported to colocalize with cortical 
actin filaments. Recently, PLCγ1 was detected in human 
T cells as a phosphoprotein [54]. CD3 activation of T 
cells was shown to cause tyrosine phosphorylation of 
PLCγ1, which is associated with a marked increase in PLC 
activity that accounts for the activation and translocation 
of PKCα and results in low expression levels of ZO-1 
and claudin-2, thereby opening TJs in the epithelium 
[55]. Our data indicate that the reduction in inflammation 
after DSS treatment of PLCγ1 conditional knockout mice 
is due to reduced intestinal barrier dysfunction via PKC 
pathway blockade and protection of TJ proteins via PKCα 
(Figure 6). 
Our data show that when PLCγ1 is lacking in IECs, 
cancer incidence is reduced. It is possible that tumor 
incidence depends on the frequency of DSS exposure 
and is associated with a PLCγ1-stimulated inflammatory 
response that affects tumor expression. Our study suggests 
that PLCγ1 signaling may be a good target for therapies to 
reduce CATI. Indeed, PLCγ1 is known to play important 
normal physiological roles, such as cell survival; and 
proliferation, as well as roles in cancer metastasis, such as 
angiogenesis and vascular permeability. The link between 
PLCγ1 activity and the IL-6/STAT3 signaling pathway 
could account for the transcription of many important 
cancer-related genes. Although we have shown that the 
knockdown of PLCγ1 induces apoptosis in the AOM-DSS 
model by mechanisms involving the downregulation of the 
IL-6/STAT3 signaling pathway, we aimed to demonstrate 
that PLCγ1 may be an effective treatment for CRC by 
blocking the IL-6/STAT3 signaling. Studies of the function 
of PLCγ1 are needed to elucidate potential novel targets 
for therapeutic intervention and provide new insights into 
the extent of PLCγ1 participation in CATI.
MATERIALS AND METHODS
Animals and induction of colitis and CAC 
PLCγ1f/f (WT) and PLCγ1 conditional knock-
out mice were generated with Villin-Cre mice [56]. The 
experiments were performed using 6–8 weeks old age-
matched mice in a C57BL/6 background. Their floxed 
littermates were used in all experiments as controls. 
Mice housing conditions and experimental protocols 
were approved by the Institutional Animal Care and Use 
Committee at Ulsan National Institute of Science and 
Technology. CAC was induced as described (Greten 
et al., 2004). Briefly, on day 1, mice were IP injected 
with 10 mg/kg AOM (Sigma- Aldrich) and maintained 
on regular diet and water for 5 days. After 5 days, mice 
received water with 2% (unless stated otherwise) DSS 
(dextran sulfate sodium, MP Biomedicals, molecular 
weight 35,000–50,000) for 5 days (DSS one cycle), 
followed by regular water for 14 days, and this protocol 
were performed during two further DSS treatment cycles 
(DSS three cycles). Mice were sacrificed at 100 days (DSS 
three cycles) and 120 days (DSS one cycle) after AOM 
injection, respectively. For acute colitis and inflammation 
studies, mice were administered 3% DSS for 5 days, 
followed by regular water for 3 days and sacrificed at the 
indicated time points. Body weights were recorded during 
DSS treatment. Colon length was analyzed after removal 
from mice and flushed with cold phosphate-buffered 
saline (PBS), opened longitudinally, following which 
tumor number and size measurements were recorded. 
One half of the distal colon was used for Western blot and 
quantitative polymerase chain reaction (qPCR) analysis. 
The other half the colon tissues were fixed as ‘‘swiss-
rolls’’ in 10% formalin solution (Sigma, #HT-501128) at 
room temperature overnight, and paraffin embedded. 
Histological analysis
Paraffin-embedded colons were cut into 5 μm thick 
sections, and serial sections were stained with H&E and 
Alcian Blue (for goblet cells). Using Scion Image for 
Windows (Zeiss), the colitis-severity and width of each 
tumor was measured and recorded.
Immunoblotting
Colon tissues were rinsed with ice-cold PBS and 
lysed using the radio-immunoprecipitation assay (RIPA) 
lysis buffer (Millipore Corporation, Billerica, MA, 
USA). Tissue lysates were centrifuged at 14,000 × g for 
30 min. The supernatant was collected, and protein was 
measured using the BCA Protein Assay Kit. The proteins 
were separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS–PAGE) gel and were 
electrophoretically transferred to polyvinylidene fluoride 
(PVDF) membrane (Millipore Corporation, Billerica, MA, 
USA). The membranes were blocked in 5% skimmed milk 
in Thermo Scientific SuperBlock (TBS) containing 0.05% 
Tween-20 (TBST) buffer for 1 h, and then incubated 
with primary antibodies overnight at 4°C. After washing 
in TBS-T buffer, the membranes were incubated with 
secondary antibodies for 1 h at room temperature. Protein 
bands were detected with Immobilon Western substrate 
(Millipore Corporation, Billerica, USA) and analyzed with 
the ChemiDoc Touch Imaging System (Bio-Rad, Hercules, 
CA, USA). 
Immunohistochemistry 
Sections of paraffin-embedded colon tissues were 
dewaxed in xylene, rehydrated, and subjected to antigen 
retrieval in 10 mM citrate buffer. Sections were blocked 
for 30 min in 1% bovine serum albumin, 0.02% Triton 
X-100, and 5% normal goat serum (NGS). Serial sections 
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were incubated with rabbit polyclonal ZO-1 antibody 
(1:200 dilution) and occludin antibody (1:200 dilution), 
followed by Cy5-conjugated goat anti-rabbit secondary 
antibody (Jackson ImmunoResearch Laboratories, Inc., 
West Grove, PA, USA). The sections were mounted using 
Vectashield with 4′,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Burlingame, CA, USA). Images 
from serial sections were acquired using an Axioskop 
inverted microscope with an AxioVision camera and 
software (Zeiss, Thornwood, NY, USA). 
RNA extraction and quantitative reverse 
transcription polymerase chain reaction 
Total RNA was extracted from distal colon 
segments or from colon tumors using TRIzol (Invitrogen, 
Carlsbad, CA, USA) and QIAGEN RNAeasy isolation kits 
(QIAGEN, Valencia, CA, USA). qRT-PCR was performed 
in triplicate using 4 μL of 1/12 diluted cDNA and SYBR 
green (Bio-Rad #1708886) in 20 μL total volume on a 
Roche 480 (Roche, Basel, Switzerland). The mRNA level 
was calculated by the cycle threshold (Ct) value and was 
normalized by glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). 
Detection of tumor mutations 
Tumor tissues were obtained by laser capture 
microdissection (LCM) from paraffin-embedded 
colons and were digested with proteinase K. Genomic 
DNA was purified by standard phenol chloroform 
extraction. Exon 3 of the β-catenin gene was amplified 
by PCR using the following specific primers: 
5′-GCTGACCTGATGGAGTTGGA-3′ and 5′- GCTACTT 
GCTCTTGCGTGAA-3′ (amplicon size = 227 bp). PCR 
products were purified and sequenced using forward and 
reverse primers. Mutations were detected by observing 
individual chromatograms.
Statistical analysis 
Data are expressed as mean ± standard error of the 
mean (SEM). Differences were analyzed by Student’s 
t test. Values of p < 0.05 were considered significant.
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